SCHEMBL1161517

SCHEMBL1161517

COc1cccc2[nH]c(CCl)nc(=O)c12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 1/20 0.48
HPGD P15428 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KCNA5 P22460 1/20 0.43
SLC2A1 P11166 1/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
HTR2C P28335 2/20 0.42
MAPT P10636 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD17B10 Q99714 1/20 0.41
PARP1 P09874 1/20 0.40
PDE3B Q13370 2/20 0.40
PDE3A Q14432 2/20 0.40
ATM Q13315 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1161436 0.81 HTT (0.42) MEN1KMT2AKDM4EALDH1A1NPC1
SCHEMBL4063142 0.79 SMN1; SMN2 (0.50) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL1161490 0.79 ERCC5 (0.43) MEN1KMT2AKDM4EALDH1A1NPC1
SCHEMBL1161451 0.78 FEN1 (0.42) SLC2A1NPC1RAB9ASMN1; SMN2PARP1
SCHEMBL6930611 0.77 RAB9A (0.48) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL1161630 0.77 NQO2 (0.48) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL6930649 0.71 TNKS (0.59) KDM4EPARP1
SCHEMBL30186048 0.71 TNKS (0.59) KDM4EPARP1
SCHEMBL7504985 0.71 TP53 (0.44) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL2767091 0.70 ALDH1A1 (0.47) HPGDMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011012622-A1 BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF GLYTL MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2011-02-03 WO disclosed